Status:
UNKNOWN
Comparing the Efficacy of 14-day Reverse Hybrid Therapy and 14-day Triple Therapy Plus Bismuth Therapy
Lead Sponsor:
Kaohsiung Veterans General Hospital.
Conditions:
Helicobacter Pylori Infection
Eligibility:
All Genders
20-90 years
Phase:
NA
Brief Summary
Reverse hybrid therapy achieves a higher eradication rate than bismuth (triple therapy plus bismuth) remains unanswered
Detailed Description
With the rising prevalence of antimicrobial resistance, the failure rate of the 7-day standard triple therapy has declined to unacceptable level (\<80%) worldwide. Several regimens were suggested to r...
Eligibility Criteria
Inclusion
- Consecutive H pylori-infected outpatients, at least 20 years of age, with endoscopically proven peptic ulcer diseases or gastritis
Exclusion
- previous H pylori-eradication therapy
- ingestion of antibiotics or bismuth within the prior 4 weeks
- patients with allergic history to the medications used
- patients with previous gastric surgery
- the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia)
- pregnant women
Key Trial Info
Start Date :
January 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
440 Patients enrolled
Trial Details
Trial ID
NCT03321773
Start Date
January 1 2017
End Date
December 1 2020
Last Update
March 14 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaohsiung Veterans General Hospital
Kaohsiung City, Taiwan, 813